Condition: Colorectal Cancer · Colon Adenoma · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The primary aim of this study is to determine the rate of total metachronous advanced neoplasia (TMAN) detection after index detection of serrated lesions (SL) \[sessile serrated polyps (SSPs), traditional serrated adenomas (TSAs)\], and metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD). We will use the database of patients diagnosed with SL or HGD at index colonoscopy with a delay in surveillance and determine the risk of advanced lesions (especially high-risk lesion and CRC detection) of these delayed colonoscopies. The aim is to determine the effects of breach of continuity of care in these patients.
This description comes directly from the study's public registry record.
Daniel von Renteln, MD, PhD · 514-890-8000 · daniel.von.renteln.med@ssss.gouv.qc.ca
Julie Fleury · 514-890-8000 · julie.fleury.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05355363